Atara Biotherapeutics, Inc. (LON:0HIY)
London · Delayed Price · Currency is GBP · Price in USD 11.92
-0.13 (-1.07%)
At close: Sep 12, 2025
Atara Biotherapeutics Employees
Atara Biotherapeutics had 153 employees as of December 31, 2024. The number of employees decreased by 72 or -32.00% compared to the previous year.
Employees
153
Change (1Y)
-72
Growth (1Y)
-32.00%
Revenue / Employee
3.62M GBP
Profits / Employee
111.31K GBP
Market Cap
59.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 153 | -72 | -32.00% |
| Dec 31, 2023 | 225 | -109 | -32.63% |
| Dec 31, 2022 | 334 | -244 | -42.21% |
| Dec 31, 2021 | 578 | 141 | 32.27% |
| Dec 31, 2020 | 437 | 44 | 11.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Atara Biotherapeutics News
- 5 weeks ago - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
- 2 months ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 2 months ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 2 months ago - Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PRNewsWire
- 2 months ago - Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) - Business Wire
- 4 months ago - Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - Business Wire
- 4 months ago - Atara Biotherapeutics GAAP EPS of $3.50, revenue of $98.15M - Seeking Alpha
- 4 months ago - Atara Biotherapeutics prices $16M public offering - Seeking Alpha